A pivotal publication detailing the efficacy and safety of secukinumab (Cosentyx) for active ankylosing spondylitis was released on 2015-01-01. The study provided insights into 16-week efficacy and 2-year long-term safety and efficacy of the drug in patients with the condition.

Background

Secukinumab is an interleukin-17A (IL-17A) inhibitor. This class of drugs works by targeting IL-17A, a cytokine involved in inflammation and immune responses. The publication focused on its role in ankylosing spondylitis, a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, leading to pain, stiffness, and potentially structural damage.

Trial design

The pivotal study, referred to as MEASURE 1 in the publication's summary, evaluated secukinumab in patients diagnosed with active ankylosing spondylitis. The trial's design focused on assessing both the short-term effectiveness and the sustained long-term profile of the drug. Specifically, it investigated 16-week efficacy and monitored 2-year long-term safety and efficacy outcomes.

Key results

The published findings highlighted the therapeutic profile of secukinumab in patients with active ankylosing spondylitis. Key outcomes reported from the study included:

What this means

The publication of this pivotal data provides important evidence for the use of secukinumab in managing active ankylosing spondylitis. The findings support its short-term efficacy, offering clinicians a treatment option to reduce disease activity within 16 weeks. Furthermore, the sustained 2-year long-term safety and efficacy data are crucial for patient management, indicating that the benefits and tolerability of the drug are maintained over an extended period for individuals living with this chronic inflammatory condition.

Source

This information was published in a pivotal article on 2015-01-01, sourced from PubMed, available via pubmed.ncbi.nlm.nih.gov. The article is titled "Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis."